Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there. Did your doctor somehow miss the recovery protocol that Pedro Bach-y-Rita used to recover fully back in 1958 with only a partial brain?

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, November 18, 2026

CASS4 Gene Directs Microglia to Contain Alzheimer’s Plaques

 Does your competent? doctor and hospital have enough brains to ensure further research occurs?

You need this because of all this.

2. Then this study came out and seems to have a range from 17-66%. December 2013.`    

3. A 20% chance in this research.   July 2013.

4. Dementia Risk Doubled in Patients Following Stroke September 2018 

The latest here:


CASS4 Gene Directs Microglia to Contain Alzheimer’s Plaques

Summary:

Neuroscientists at the University of Virginia School of Medicine have uncovered the elusive biological mechanism of CASS4, a prominent genetic risk factor for Alzheimer’s disease. In a study published in the Journal of Experimental Medicine, researchers led by Dr. John Lukens demonstrated that CASS4 acts not within neurons as previously assumed, but directly within microglia, the brain’s resident immune cells.

The gene functions as a master regulator enabling microglia to surround, contain, and tightly compact toxic amyloid-beta plaques into manageable clusters. When CASS4 activity is impaired, microglia fail to envelop plaques, allowing neurotoxic proteins to spread unrestrained, triggering synaptic destruction, neuronal death, and rapid cognitive decline.

Key Facts:

  • Paradigm Shift to Glial Immunity: While earlier hypotheses assumed the CASS4 risk gene operated inside neurons, UVA Health researchers proved it functions predominantly inside microglia to direct immune surveillance and plaque compaction.
  • Loss of Plaque Barrier Defense: Disruption of CASS4 leaves microglia incapable of effectively corralling amyloid-beta deposits; uncompacted plaques expand rapidly, accelerating local neurotoxicity and cognitive deterioration in preclinical models.
  • Therapeutic and Diagnostic Potential: Defective CASS4 signaling may serve as an early diagnostic biomarker for Alzheimer’s risk, while therapies that enhance or restore its function offer an untapped immunotherapeutic avenue across neurodegenerative diseases.

Source: University of Virginia / Journal of Experimental Medicine

More than six million Americans live with Alzheimer’s disease, a progressive neurodegenerative disorder that erodes memory, executive function, and personal identity. Ranked as the sixth leading cause of death in the United States, Alzheimer’s is characterized pathologically by two hallmark protein aggregations: extracellular amyloid-beta plaques and intraneuronal neurofibrillary tangles composed of hyperphosphorylated tau.

Large-scale genome-wide association studies (GWAS) have repeatedly flagged CASS4 (Cas Scaffold Protein Family Member 4) as a significant genetic risk locus for late-onset Alzheimer’s disease. However, despite its consistent link to dementia risk, its molecular function and cellular site of action inside the brain remained unknown.

Now, a research team at the University of Virginia School of Medicine led by Dr. John Lukens has resolved this question.

Publishing in the Journal of Experimental Medicine, the investigators reveal that CASS4 operates as a critical genetic coordinator of microglia, the central nervous system’s specialized immune scavengers. Rather than serving an intrinsic neuronal role, CASS4 orchestrates the microglial machinery required to corral and compact neurotoxic debris, preventing widespread collateral damage to neighboring circuits.

Microglia as the Brain’s Garbage Disposal

Under healthy physiological conditions, microglia constantly survey brain parenchyma with motile branches. When toxic amyloid-beta monomers oligomerize into fibrillar deposits, healthy microglia migrate toward the site, forming a dense protective barrier around the plaque core.

This microglial wall physically isolates the toxic fibrils and mechanically compacts them into dense, tightly packaged bundles, preventing neurotoxic oligomers from diffusing outward and poisoning adjacent neuronal synapses.

When Lukens’ team disrupted CASS4 function in preclinical models, this defense collapsed:

  • Impaired Plaque Compaction: Microglia lost their targeted chemotactic response to nascent plaques, failing to form cohesive protective barriers around amyloid aggregates.
  • Accelerated Plaque Expansion: Without compaction, amyloid-beta grew rapidly in diffuse, unregulated geometries, exposing wider swaths of surrounding brain tissue to toxic oligomers.
  • Synaptic Damage and Cognitive Decline: The unchecked spread of uncompacted plaques triggered downstream neuronal dysfunction, dendritic loss, and accelerated cognitive impairment.

“These findings break new ground in our understanding of how this genetic risk factor contributes to Alzheimer’s disease,” said Dr. Lukens, director of UVA’s Harrison Family Translational Research Center in Alzheimer’s and Neurodegenerative Diseases. “Our work further suggests that defective CASS4 activity may serve as an early-onset biomarker to detect Alzheimer’s and that therapeutic strategies which boost its function may offer a much-needed approach to treat this devastating brain disease.”

Shifting the Therapeutic Paradigm

Historically, neurodegenerative drug development focused heavily on targeting neurons directly or attempting to chemically dissolve amyloid aggregates after they formed. The UVA team’s findings provide evidence for neuroimmunological modulation as an alternative strategy.

“Despite CASS4 being an Alzheimer’s risk gene, really nothing is known about what this gene does or how it affects the brain during disease. Our lab sought to address this major knowledge gap with this paper,” explained lead author Addie Walsh, a UVA physiology graduate student who conducted the foundational experiments before heading to Novartis’ Neurodegeneration Team to continue microglial research. “These are important findings because they give us new insight into how this understudied AD risk gene functions in the brain and suggest that CASS4 may normally help microglia respond to amyloid pathology.”

The researchers demonstrated that the loss of CASS4 causes broad downstream dysregulation of microglial transcriptional networks, influencing cellular clearance mechanisms relevant to multiple protein-misfolding disorders.

“Many in the field initially presumed that CASS4 was likely functioning in neurons to influence Alzheimer’s. Our findings shift this paradigm by proving that CASS4 predominantly acts through the immune system,” Lukens noted. “This is particularly exciting, as it has only been in recent years that immune-targeting strategies have been considered for the treatment of neurodegenerative diseases, and this remains an untapped therapeutic avenue with tremendous potential.”

Translational Opportunities at the Manning Institute

Lukens’ laboratory, affiliated with both the Harrison Family Translational Research Center and UVA’s Center for Brain Immunology and Glia (BIG Center), is now leveraging resources within the newly launched Paul and Diane Manning Institute of Biotechnology. The institute is specifically engineered to translate foundational biomedical discoveries into clinically actionable therapeutics.

The investigators are working to screen small-molecule agonists and gene-therapy vectors capable of upregulating CASS4 expression or mimicking its scaffolding activity within human microglia.

By restoring the brain’s endogenous capacity to compact and neutralize metabolic toxins, future immunotherapies targeting the CASS4 pathway could offer a targeted strategy to halt Alzheimer’s progression before extensive neuronal loss occurs.

Questions and Answers

What is the CASS4 gene, and how does it relate to Alzheimer’s disease?

CASS4 is a genetic risk factor repeatedly identified in genome-wide association studies for Alzheimer’s disease. This study reveals that CASS4 directs microglia to act as the brain’s “trash compactors,” forming protective physical barriers around toxic amyloid-beta plaques to minimize neurotoxic exposure.

What happens to the brain when CASS4 function is disrupted?

When CASS4 is inactive or impaired, microglia fail to surround and compress amyloid-beta plaques. As a result, the plaques grow faster, spread more aggressively into surrounding tissue, damage nearby neurons, and accelerate memory loss and cognitive decline.

Why does this study change how scientists view Alzheimer’s treatments?

Most previous research assumed CASS4 operated within neurons. Proving that it acts through microglia confirms that immune dysfunction is central to Alzheimer’s pathology, opening opportunities for therapies designed to boost microglial clearance rather than solely targeting neuronal pathways.

Editorial Notes:

  • This article was edited by a Neuroscience News editor.
  • Journal paper reviewed in full.
  • Additional context added by our staff.

  • Media Contact: Josh Barney
  • Source: University of Virginia
  • Image Credit: Image credited to Neuroscience News
  • Original Research is Open Access: Journal of Experimental Medicine (Oct 1, 2026). “Alzheimer’s genetic risk factor CASS4 controls microglial focal adhesion biology and amyloidosis.” Authors: Adeline E. Walsh, Benjamin A. Davis, Joshua D. Samuels, William A. Mills, III, Jessica M. Thanos, Alexis M. Johnson, Katelyn A. Moore, Michael A. Puchalski, Eric J. Steacy, Benjamin W. Wendell, Amélie Daugherty-Lopès, Adrian A. Shimpi, Ukpong B. Eyo, and John R. Lukens.
  • DOI: 10.1084/jem.20260104

Intensive versus standard statin therapy in acute ischemic stroke: a comparative study on the risk of pneumonia and multidrug-resistant bacterial infections

 Still don't have an immediate statin protocol therapy for better recovery? Why hasn't everyone here been fired yet?

Your competent? doctor immediately prescribed statins post stroke based on earlier research, right? NO? And still hasn't been fired yet?

1. Statins.

tested in rats from 2003

http://Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke  

Simvastatin Attenuates Stroke-induced Splenic Atrophy and Lung Susceptibility to Spontaneous Bacterial Infection in Mice

Or,

Simvastatin attenuates axonal injury after experimental traumatic brain injury and promotes neurite outgrowth of primary cortical neurons 

October 2012

tested in humans, March 2011

http://www.medwirenews.com/39/91658/Stroke/Acute_statin_therapy_improves_survival_after_ischemic_stroke.html

And now lost even to the Wayback Machine

So, I think this below is the actual research.

Association Between Acute Statin Therapy, Survival, and Improved Functional Outcome After Ischemic Stroke April 2011 

The latest here: 

Intensive versus standard statin therapy in acute ischemic stroke: a comparative study on the risk of pneumonia and multidrug-resistant bacterial infections


  • 1. Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

  • 2. Department of Clinical Laboratory, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine, Wenzhou, Zhejiang, China

Abstract

Background: 


The use of intensive statin therapy in acute ischemic stroke (AIS) is common; however, its association with post-stroke pneumonia (PSP) remains uncertain. This study aimed to determine whether intensive-dose atorvastatin (≥40 mg/d) increases the risk, severity, or incidence of multidrug-resistant (MDR) bacterial infections in PSP compared to standard-dose therapy (20 mg/d).


Methods: 


We retrospectively analyzed 4,843 AIS patients admitted to the First Affiliated Hospital of Wenzhou Medical University between January 2020 and January 2022. After applying inclusion and exclusion criteria, 3,199 patients were included. Propensity score matching (PSM) was used to balance baseline characteristics between the intensive and standard atorvastatin groups. The incidence of PSP, pneumonia severity (evaluated by CURB-65 scores), and MDR bacterial infection rates were compared. Multivariate logistic regression was applied to identify independent risk factors for PSP.


Results: 


After PSM, no significant difference was observed in PSP incidence between the intensive and standard atorvastatin groups (8.8% vs. 8.3%, p = 0.691). Multivariate regression confirmed that intensive treatment was not associated with increased PSP risk, either before (OR = 1.074, 95% CI: 0.756–1.525) or after matching (OR = 1.002, 95% CI: 0.672–1.492). Among the 173 PSP patients, there were no significant differences in the proportion of severe pneumonia (21.4% vs. 20.2%, p = 0.863) or MDR bacterial infection incidence (9.5% vs. 10.1%, p = 0.897) between the two groups.


Conclusion: 


High-intensity atorvastatin therapy during the acute phase of ischemic stroke did not increase the risk or severity of pneumonia, nor did it elevate MDR bacterial infections. These findings suggest that intensive atorvastatin therapy is not associated with an increased risk of PSP and offer insights for optimizing clinical treatment strategies.

Frailty combined with nutritional risk for predicting stroke-associated pneumonia: a cohort study based on a nomogram model

 

Just maybe you'd rather prevent pneumonia that predict it. Or would you rather continue with stupidity? I'd have you all fired for gross incompetence in not writing a pneumonia prevention protocol instead of this crapola!

How about this vaccine!

The latest here:

Frailty combined with nutritional risk for predicting stroke-associated pneumonia: a cohort study based on a nomogram model


  • K

    Kailibinuer Aimaier 1

  • J

    Jiarui Xiong 1

  • C

    Chunrui Liu 1

  • S

    Shuhong Zhou 2

  • G

    Guangwei Liu 1*

  • Feng Li

    Feng Li 1*

  • 1. Department of Neurology & Nursing, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

  • 2. College of Culture and Tourism, Chongqing Business Vocational College, Chongqing, China

Abstract

Introduction: 


Stroke-associated pneumonia (SAP) is a common and serious complication in patients with acute severe stroke, and existing risk assessment tools have limited predictive accuracy in critically ill populations. This study innovatively incorporated frailty and nutritional risk, which reflect stress tolerance and overall physiological reserve, into an early SAP prediction model.


Methods: 


A retrospective cohort study was conducted on 293 critically ill stroke patients admitted to the Neurocritical Care Unit of the First Affiliated Hospital of Chongqing Medical University between 2013 and 2024. Collect clinical characteristics and laboratory indicators of patients, assess their frailty status and nutritional risk, and analyze the additive interaction effect between the two on the occurrence of SAP. Independent predictors were identified through multivariate logistic regression and incorporated into a visual nomogram. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), calibration plots, decision curve analysis, and 10-fold cross-validation.


Results: 


A total of 293 patients with severe stroke were included in this study, among whom 126 (43%) developed SAP. The results of the additive interaction analysis showed a positive additive interaction between frailty and nutritional risk in the development of SAP, with an attributable proportion (AP) of 0.711 (95% CI = 0.358 ~ 1.065) and a synergy index (SI) of 3.694 (95% CI = 1.200 ~ 11.364). A SAP risk prediction model incorporating age, nasogastric tube use, neutrophil-to-lymphocyte ratio (NLR), frailty status, and nutritional risk demonstrated good discriminative performance, with an area under the curve (AUC) of 0.848, which was significantly higher than that of the conventional SAP prediction score (ISAN score: AUC = 0.589). Internal validation showed that the model achieved an accuracy of 73.93%, sensitivity of 77.30%, and specificity of 71.95%, indicating good stability. The calibration curve demonstrated good agreement between predicted and observed outcomes. Decision curve analysis (DCA) indicated that the model provided substantially greater clinical net benefit than the ISAN score.


Discussion: 

This study is the first to integrate frailty and nutritional risk into an SAP prediction model, significantly improving early risk identification and providing an innovative, practical tool for precision prevention and targeted intervention in critically ill stroke patients.

Clinical software for unsupervised automated net water uptake analysis predicts futile recanalization in acute ischemic stroke

 

I don't think you identified cause and effect properly, measuring Rankin scores has nothing directly to do with reperfusion! My god, the blithering stupidity out there is astounding!

 What followup research did you do ensure reperfusion will work completely every time? Oh NO, YOU INCOMPETENTLY DID NOTHING, right? Predicting failure is totally fucking useless! 

But this futile recanalization probably is because you did NOTHING to stop the 5 causes of the neuronal cascade of death in the first week and thus letting die hundreds of millions to billions of neurons! The recanalization worked, you just don't recognize this neuronal cascade of death occurring! 

You are COMPLETELY FUCKING INCOMPETENT FOR NOT KNOWING THAT! Your mentors are just as incompetent!

You really don't  know what the fuck you are doing in stroke, so get the hell out!

Clinical software for unsupervised automated net water uptake analysis predicts futile recanalization in acute ischemic stroke


  • Abdallah Aburub

    Abdallah Aburub 1† *

  • O

    Oussama Dob 1†

  • M

    Mariana Gurschi 1

  • Y

    Yashar Aghazadeh 1

  • J

    Jumana Jaber 1

  • Z

    Zaid Al-Tamimi 2

  • Z

    Zaid Samhan 3

  • L

    Lars Timmermann 4

  • Christopher Nimsky

  • Peter Sporns

  • Gabriel Broocks

  • A

    André Kemmling 1,9‡

  • 1. Department of Diagnostic and Interventional Neuroradiology, Philipps University of Marburg, Marburg, Germany

  • 2. Clinic of Diagnostic and Interventional Radiology, Philipps University of Marburg, Marburg, Germany

Abstract

Objectives: 


This study aimed to determine whether automated net water uptake (NWU) measured on admission non-contrast computed tomography (CT) independently predicts futile recanalization (FR) in anterior-circulation large vessel occlusion (LVO) stroke treated with endovascular thrombectomy (EVT).


Methods: 


This was a retrospective single-center cohort study that included consecutive patients presenting at a tertiary care stroke center between January 2023 and April 2025. Patients were included if they presented with an anterior circulation LVO and had successful recanalization (mTICI 2b–3). An automated platform (VEOcore/MRAY) provided the Alberta Stroke Program Early CT Score (ASPECTS), perfusion metrics, and NWU. Associations with FR were analyzed using logistic regression. Discrimination was evaluated using receiver operating characteristic (ROC) analysis and Youden’s J statistic to identify an optimal NWU threshold, reporting the area under the curve (AUC), sensitivity, specificity, and predictive values.


Results: 

Among 91 patients, 62 (68.1%) achieved recanalization with a 90-day modified Rankin Scale (mRS) score of 0–4, and 29 (31.9%) met the criteria for FR (mRS score 5–6). Those with FR were older (81.6 ± 8.3 vs. 76.9 ± 10.7 years; p = 0.044) and had more severe strokes at presentation (median National Institutes of Health Stroke Scale [NIHSS] score of 16 [13–20] vs. 9.5 [6–15]; p < 0.001). NWU in the core was higher in FR (21.9% [7.0–29.4]) than in non-FR cases (3.0% [0.5–7.3]; p < 0.001) and correlated with 90-day mRS (Pearson r = 0.602; 95% CI 0.452–0.719; p < 0.001). In multivariable models, NWU remained independently associated with FR (odds ratio [OR] 1.15; 95% CI 1.06–1.24; p < 0.001).


Conclusion: 


Automated NWU on admission CT is an independent, strongly discriminative predictor of FR and 90-day disability. A tiered strategy using >11.5% as a risk flag and >17.5% as a high-specificity rule-in threshold may enhance early triage, prognostication, and clinical trial stratification. Prospective multicenter validation is warranted.